Illumina has named Jacob Thaysen as its next chief executive, nearly three months after the previous CEO of the gene-sequencing company departed during a proxy fight with activist investor Carl Icahn.
His appointment follows the abrupt resignation of Francis deSouza, who left in June after antitrust authorities in the U.S. and Europe challenged the company’s $7.1 billion deal for cancer-test developer Grail, drawing the ire of Icahn.
Thaysen, 48 years old, will take the helm of Illumina on Sept. 25, the company said Tuesday. Thaysen comes from Agilent Technologies, where he had run its largest analytical-lab unit.
Read the full story on The Wall Street Journal here.